A computer system and method for tracking a companion animal and alerting an owner of the companion animal when the companion animal is lost may include a server generating a web page associated with a near-field-communication (NFC) portion of an electronic tag. The electronic tag may be coupled to the companion animal with a mechanical device. The server may generate a geo-fence that is associated with the electronic tag and the server may monitor the geo-fence to determine if the electronic tag has exited the geo-fence. The server may send a message to the web page if the electronic tag has exited the geo-fence. The server may then send an alert to a portable computing device if the electronic tag has exited the geo-fence. The server may send a command to the electronic tag to change from a first rate to a second rate for a device identifier reporting rate.
A computer-implemented method and system for tracking near-field communication (NFC)-enabled animals with a portable computing device (PCD) (i.e. mobile phone) may include providing an NFC-tag comprising memory in which the memory contains a unique identifier. The NFC-tag may be coupled to an animal and then the NFC-tag may be scanned with the PCD. A tag identification server may determine if data from the NFC-tag exists in a database and then transmits an animal production facility identifier and one or more animal records associated with data from the NFC-tag from the tag identification server if the data from the NFC-tag exists in the database. Access to a secure memory area on the portable computing device containing a complete set of animal records for an entire animal facility may be granted if the software identifier matches the animal production facility identifier received from the tag identification server.
S. suisS. suisS. suisS. suis, and kits for use with such methods and compositions. The invention further provides a comprehensive, unambiguous method of capsular typing based on whole genome sequencing and bioinformatics. This capsular typing approach can accurately identify serotypes even when strains possess novel capsular loci and can be used to determine which strains to include when formulating vaccines, including herd specific vaccines.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
4.
PESTICIDAL AND PARASITICIDAL PYRAZOLE-ISOXAZOLINE COMPOUNDS
The present invention relates to pesticidal and parasiticidal isoxazoline of formula (I) and salts thereof: wherein variables R1, P, Y and Q are described herein are as defined in the description. The invention also relates to parasiticidal and pesticidal compositions comprising the isoxazoline compounds of formula (I), processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
The present invention encompasses a stabilized parasiticidal granule composition comprising a macrocyclic lactone compound and an insect growth regulator. The invention also encompasses methods of making and methods of using the granule for treating, controlling or preventing parasitic infestation or parasitic infection in an animal.
A01N 43/68 - 1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms with two or three nitrogen atoms directly attached to ring carbon atoms
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
A61K 39/00 - Medicinal preparations containing antigens or antibodies
7.
IN VIVO MODEL FOR PARASITIC WORM INFECTION AND METHODS FOR EVALUATING ANTIPARASITIC COMPOUNDS, INCLUDING COMPOUNDS ACTIVE AGAINST CANINE HEARTWORM
The following discloses a novel model for parasitic worm infection, which is useful for screening for and evaluating the efficacy of antiparasitic agents. In particular, the disclosure provides an immunocompromised mouse model that, for the first time, supports advanced development of Dirofilaria immitis (Di) parasites outside of their definitive hosts. As described herein, early-stage larval forms of Di, the causative agent of Canine Heartworm disease, not only persist in this model, but they develop into mature worms.
A01N 43/72 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 47/18 - Carbamic acid derivatives, i.e. containing the group —O—CO—NThio-analogues thereof containing a —O—CO—N group, or a thio-analogue thereof, directly attached to a heterocyclic or cycloaliphatic ring
The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.
This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof.
The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof cyclic, e.g. valinomycins
A01N 43/72 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms
11.
RECOMBINANT VECTORS EXPRESSING ANTIGENS OF AVIAN INFLUENZA VIRUS AND USES THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
Inventor
Pritchard, Joyce
Mebatsion, Teshome
Swayne, David
Abstract
The present invention provides recombinant viral vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant viral vectors, polyvalent vaccines comprising the recombinant viral vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant viral vectors.
The present invention relates to pesticidal and parasiticidal isoxazoline of formula (I) and salts thereof: Formula (I) wherein variables B1, B2, B3, R1, P1, P2, Y and Q are described herein are as defined in the description. The invention also relates to parasiticidal and pesticidal compositions comprising the isoxazoline compounds of formula (I), processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 263/16 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The present intention provides for, inter alia, a method for reducing a withdrawal period when treating livestock for parasitic infestations, which comprises administering an effective amount of a parasiticidal composition comprising an (S) enantiomer of an isoxazoline compound of the formula (S)-1 or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein, and an inert carrier or formulation adjuvant; wherein the composition contains less than 10% by weight of an (R) enantiomer of an isoxazoline compound or a pharmaceutically acceptable salt thereof. Moreover, the present invention further provides for method for reducing at least one unwanted effect while treating a non-human animal for a parasitic infestation by administering an effective amount of a parasiticidal composition comprising an (S) enantiomer of an isoxazoline compound of the formula (S)-l or a pharmaceutically acceptable salt thereof and an inert carrier or formulation adjuvant, wherein the composition contains less than 10% by weight of an (R) enantiomer of an isoxazoline compound or a pharmaceutically acceptable salt thereof.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
The invention relates to a candling apparatus for the rapid discrimination, removal and relocation of non-live avian eggs. The invention further relates to methods of use of the candling apparatus for the candling, removal and relocation of avian eggs.
The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
The invention relates to a machine for labeling "blank-labeled" cryogenically-frozen vials or ampoules, which contain heat-labile biological materials, and to which a laser-light sensitive material had been applied prior to freezing. Accordingly, the machine has been designed to maintain the integrity of the biological materials throughout all phases of the labeling process. The machine generally comprises a master control system; a programmable user interface; a frame; cryogenic freezer assemblies, for keeping the vials at the required low temperatures; an infeed assembly, configured to receive and position blank-labeled cryogenic vials; a cryostatic labeling/quality control tunnel, wherein the vials are maintained at the required temperature, labeled by laser ablation, and checked for quality; and, an outfeed assembly. The machine further comprises a means for transporting the vials from the infeed assembly to the tunnel, and from the tunnel to the outfeed assembly. Vials labeled according to the instant disclosure are ultimately manually or automatically loaded into cryogenic shipping containers.
The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative- containing multi-dose formulations. The preservative-containing multi-dose formulations exhibit resistance to one or more contaminating microorganisms, and have advantageous properties with respect to long term stability of biological and small molecule active ingredients.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
18.
POWERED INJECTION DEVICE FOR DELIVERING MULTIPLE LIQUID FORMULATIONS, INCLUDING VACCINES
The invention relates to hand-held, powered injection devices, for administering fluids, including vaccines, to animals. The invention further relates to methods of use of the powered injection device for vaccinating avian animals. Powered injection devices according to the instant disclosure are ergonomically friendly, and offer rapid and consistent dosing, particularly for avian animals.
The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one indole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
H03K 5/04 - Shaping pulses by increasing durationShaping pulses by decreasing duration
H03K 7/00 - Modulating pulses with a continuously-variable modulating signal
20.
PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ISOXAZOLINE COMPOUNDS - CRYSTALLINE TOLUENE SOLVATE OF (S)-AFOXOLANER
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transfer catalysts and to a crystalline toluene solvate form of (S)-afoxolaner.
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 453/04 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e.g., a canine), the host will generate antibodies as part of its robust immune response to the antigen. As the antibodies circulate through the host's plasma, heartworm larvae will consume the antibodies as they feed on the plasma. The antibodies will then act on internal targets of the worm recognized as antigens.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
22.
SINGLE OR DUAL TECHNOLOGY ANIMAL TAGS AND SYSTEM AND METHOD OF USING THE SAME
A system and method are disclosed for tracking animals, which may include production animals as well as pets. The system and method may comprise a tag system that is attached to an animal that generally has at least a near-field-communication (NFC) tag. The tag system comprises at least an NFC tag and a radio-frequency identification (RFID) tag. For NFC tags, such tags may be read with a portable computing device, such as a mobile telephone running NFC reader application software. The phone may communicate with a communications network and ultimately a computer server in order to relay information received from a respective electronic tag. The electronic tags may be fastened, embedded, or ingested by an animal. The electronic tags may be part of a mechanical coupling. Each mechanical coupling may comprise a different structure depending on the whether the tags are fastened to, embedded in, or ingested by the animal.
This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutically acceptable additive or excipient. This invention also provides new isoxazoline active agents with long-lasting efficacy against ectoparasites. The invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the novel isoxazoline compounds and long-acting injectable compositions of the invention to the animal in need thereof.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
24.
Apparatus and methods for labeling vials or ampoules stored at temperatures as low as -200° C
This invention relates to an apparatus and method for applying writings and other markings to a frozen vial or ampoule, which is filled with biological material, and which is held at temperatures between about −70° C. and about −196° C. More particularly, the invention relates to a laser marking method that allows frozen vials to be labeled, while maintaining the integrity of the biological material contained therein.
B41M 5/24 - Ablative recording, e.g. by burning marksSpark recording
B41J 3/407 - Typewriters or selective printing or marking mechanisms characterised by the purpose for which they are constructed for marking on special material
A61J 1/18 - Arrangements for indicating condition of container contents, e.g. sterile condition
25.
Mannheimia haemolytica vaccines and methods of making and use
M. haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
C07K 14/285 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
The present invention encompasses an effervescent Grape extract plus selenium composition which improves stress response. The invention also encompasses methods of improving stress response, such as stress response to vaccination or weaning, by administration of the composition. The invention also encompasses methods of producing meat with improved quality by raising an animal on a diet supplemented with an effervescent Grape extract plus selenium composition.
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HOMELAND SECURITY (USA)
Inventor
Widener, Justin
Woodyward, Leszlie
Siger, Leonardo
Ettyreddy, Damodar
Gall, Jason
Mcvey, Duncan
Burrage, Tom
Brough, Douglas
Abstract
The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
29.
RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS
The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A01N 43/72 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms
C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof cyclic, e.g. valinomycins
32.
METHODS OF PROVIDING GRASS GROWTH AND NEMATODE SUITABILITY INDICES TO ASSIST DETERMINATION OF TIMING OF PARASITICIDE TREATMENT
The present invention builds and conveys to users in need thereof a Grass Growth Index (GGI) and a Nematode Suitability Index (NSI), to assist the determination of whether and when to administer parasiticides to grazing livestock, such as bovine, ovine and caprine animals. In particular, the invention relates to a computer-implemented method whereby GGI and NSI are calculated based upon both user-supplied information (e.g. grass/forage type and location data) and user-independent information (e.g. weather and environmental condition data associated with the location over time, and grass and nematode growth parameters). Importantly, the disclosed methods provide users with information as to when and where their herds of grazing animals may be at the greatest risk of parasite infestation.
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling
33.
Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy's disease)
This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.
The present invention relates to various topical veterinary compositions comprising fipronil, an insect growth regulator, and a veterinarily acceptable carrier.
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
A01N 47/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
A01N 49/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds containing the group wherein m+n≥1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group wherein A means a carbon atom or Y, n ≥ 0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
A method of treating the skin or hair on a dog containing an effective amount of an ectoparasiticide previously applied to the skin or hair, comprising applying a quantity of a cleansing composition directly to the skin or hair, wherein the treatment does not result in reducing the efficacy of the ectoparasiticide against adult fleas (C. felis) or adult ticks (R. sanguineus) below 90% efficacy for at least a month after application of the ectoparasiticide; wherein the cleansing composition comprises about 1-3 % glycerin; about 2-4% silicone copolyol esters, water and is essentially free of surfactant.
A61K 8/892 - Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a hydroxy group, e.g. dimethiconol
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
A pet care composition comprising Verbascum Thapsus extract, rhamnose, glucose, glucuronic acid and a cosmetically acceptable carrier; and uses thereof.
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
39.
Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.
A storage and manual dispenser apparatus for dispensing a pharmacetutical liquid under atmospheric pressure. This apparatus retains the liquid in a controlled and stable enviorment during storage.
The disclosure relates to a spray applicator system for accurately and precisely dosing liquid formulations, including vaccines and probiotic formulations, to caged avian animals. In particular, the disclosure relates to spray applicators, having improved acceptance by the avian animals, relative to more disruptive prior spray applicators. The disclosed automated caged spray applicator system is designed to attach to and function with automated poultry feeding systems, routinely used in poultry house settings.
A61D 7/00 - Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
A61D 1/02 - Trocars or cannulas for teatsVaccination appliances
A01K 13/00 - Devices for grooming or caring of animals, e.g. curry-combsFetlock ringsTail-holdersDevices for preventing crib-bitingWashing devicesProtection against weather conditions or insects
The present invention relates to novel anthelmintic compounds of formula (I) below:
3, R, R′, m, n and q are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
43.
LIVE ATTENUATED HETEROLOGOUS VACCINE FOR LEPTOSPIRA
The present invention provides compositions or vaccines that contain a recombinant or an attenuated Leptospira interrogans that elicit an immune response in animals against Leptospira infection, including compositions comprising said recombinant or attenuated L. interrogans, methods of vaccination against Leptospira, and kits for use with such methods and compositions.
The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
The present invention encompasses FCV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FCV antigens. The invention also encompasses recombinant vectors encoding and expressing FCV antigens, epitopes or immunogens which can be used to protect animals against FCV infection.
This invention relates to high throughput methods of determining a viral titer. The instant invention addresses the need for a more rapid and cost effective method of quantitating infectious viral particles in a sample.
The present invention relates to novel dihydroazole of formula (I) and salts thereof:
2, G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV.
The present invention relates to canine influenza virus strains, and vaccines and compositions. The present invention also relates to reagents and methods allowing their detection, methods of vaccination as well as methods of producing these reagents and vaccines.
The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV.
The disclosure provides a cell freezing and storage bag assembly and a method for using the assembly in banking eukaryotic cells for later seed train expansion. The bag is constructed principally of fluorinated ethylene propylene (FEP) fabric, and is designed to be filled such that the cell suspension has a very thin cross-section. The bag design includes at least an inlet conduit and an outlet or inoculation conduit, which can be sterilely welded to the source of the eukaryotic cells. The use of at least two sterile-weldable conduits allows for “closed system” filling of the bags, which significantly reduces the risk of contamination relative to other cell-banking methods. The bag also include a sleeve, which can be thermo-welded to form an enclosure, which protects the inlet and outlet conduits against contamination and mechanical damage during freezing, storage and subsequent thawing. In the method, once each bag is filled, its corresponding inlet conduit is sealed, and both the inlet and outlet conduits are enclosed within the bag's sleeve. This closed system method obviates the need for sterile environments (e.g. laminar flow unit).
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
53.
COMPOSITIONS CONTAINING ANTIMICROBIAL IGY ANTIBODIES, FOR TREATMENT AND PREVENTION OF DISORDERS AND DISEASES CAUSED BY ORAL HEALTH COMPROMISING (OHC) MICROORGANISMS
The present invention encompasses methods and compositions for inhibiting, treating, and preventing dental diseases in human and non-human animals, particularly domesticated companion animals.
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof cyclic, e.g. valinomycins
A01N 43/72 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms
C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
55.
INLINE AVIAN SPRAY APPLICATOR WITH RAPIDLY-ACTUATING AUTOMATIC SPRAY NOZZLES
The invention relates to spray applicator devices and methods of use for vaccinating, or administering probiotics to, avian animals. Said automated spray applicator device comprises a housing, at least one rapidly actuatable automatic spray nozzle, a programmable spray module, for controlling the automatic spray nozzle(s), and optionally a source of pressurized air for supplying pressure to the fluid prior to its entry into the spray nozzles; wherein the programmable spray module is in electrical, pneumatic or hydraulic connection with the at least one automatic spray nozzle; wherein the automatic spray nozzle(s) is(are) in fluid communication with a fluid reservoir/tank; and wherein the automatic spray nozzle comprises an electrical, pneumatic or hydraulic actuator and a nozzle tip.
The disclosure relates to an extended-range spray applicator, and methods of making and use thereof, for dosing vaccines and/or probiotics to avian animals at a distance.
A61D 1/02 - Trocars or cannulas for teatsVaccination appliances
B05B 9/08 - Apparatus to be carried on or by a person, e.g. of knapsack type
B05B 3/10 - Spraying or sprinkling apparatus with moving outlet elements or moving deflecting elements with rotating elements discharging over substantially the whole periphery of the rotating member
B05B 1/28 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means with integral means for shielding the discharged liquid or other fluent material, e.g. to limit area of sprayNozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means with integral means for catching drips or collecting surplus liquid or other fluent material
57.
METHOD FOR PORCINE CIRCOVIRUS PRODUCTION AND PCV2 VACCINES
This invention relates to a method for rapid production of PCV2 such that an optimum yield of the virus can be obtained. This invention also relates to the vaccine useful against PCV2 which includes the PCV2 propagated using such a method.
This invention relates to extended release injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a pharmaceutically acceptable polymer, and a solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the extended release injectable formulations of the invention to the animal in need thereof.
The present invention relates to a veterinary composition comprising an effective amount of at least one cyclic depsipeptide and at least one macrocyclic lactone; and a pharmaceutically acceptable carrier, for the treatment or prophylaxis of parasitic infection in a mammal wherein the parasite shows resistance to treatment or prophylaxis with the macrocyclic lactone alone.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.
C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
C07D 235/08 - Radicals containing only hydrogen and carbon atoms
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
61.
LONG-ACTING INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF
This invention relates to long-acting injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a poloxamer, and a co-solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the long-acting injectable formulations of the invention to the animal in need thereof.
The present invention provides compositions and methods for eliciting heterologous protective immunity in animals against Leptospira spp. The Leptospira spp. immunoprotective peptides disclosed herein elicit protective immunity against subsequent challenge or exposure to at least two Leptospira spp. serovars.
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
63.
Parasiticidal compositions comprising multiple active agents, methods and uses thereof
This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising at least one 1-arylpyrazole, at least one macrocyclic lactone, at least one insect growth regulator, and at least one anthelmintic compound in combination with a pharmaceutically acceptable carrier. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 47/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
A01N 49/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds containing the group wherein m+n≥1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group wherein A means a carbon atom or Y, n ≥ 0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
The present invention relates to novel anthelmintic compounds of formula (IA) below: wherein, Y is selected from the group consisting of -H, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkyl, haloalkyl, and alkoxyalkyl; and Z is selected from the group consisting of aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkyl, haloalkyl, and alkoxyalkyl. Variables Ring A, Ring B, Ring C, X1, X6, and X8 are as defined herein. The invention also relates to parasiticidal compositions comprising the compounds, and methods and uses of the compounds for treating and preventing parasitic infections and infestations in animals.
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
M. haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
C07K 14/285 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.
The present invention relates to novel anthelmintic compounds of formula (I) below:
8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 215/42 - Nitrogen atoms attached in position 4
C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
C07D 295/215 - Radicals derived from nitrogen analogues of carbonic acid
C07D 307/14 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 235/16 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 295/16 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
C07D 333/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
68.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE DETECTION OF ANTI-MYCOPLASMA HYORHINIS IGG IN SWINE SERUM
This disclosure presents an Enzyme-Linked Immunosorbent Assay (ELISA) for the selective detection of anti-Mycoplasma hyorhinis IgG in porcine serum, which may contain antibodies specific to multiple other Mycoplasma spp.
C07K 14/30 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
The present invention relates to microneedle vaccine formulations, as well as methods of use thereof to provide animals, including canines, protective immunity against infection and disease caused by rabies viruses. Once placed onto the skin of the animals, the microneedle formulations dissolve quickly into the surrounding skin, where the antigens then elicit in the animals high and protective levels of rabies virus neutralizing antibodies.
The invention provides for spot-on formulations comprising fipronil in a high concentration for the treatment or prophylaxis of parasites of mammals and birds, and in particular, cats, dogs, horses, chickens, sheep and cattle with the aim of ridding these animals of all the parasites commonly encountered by birds and mammals. The invention also provides for effective and lasting destruction of ectoparasites, such as fleas, ticks, itch mites and lice, and of endoparasites, nematodes, such as filariae, and roundworms of the digestive tract of animals and humans.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 47/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
A01N 49/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds containing the group wherein m+n≥1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group wherein A means a carbon atom or Y, n ≥ 0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
This invention relates to an apparatus and method for applying writings and other markings to a frozen vial or ampoule, which is filled with biological material, and which is held at temperatures between about -70 °C and about -196 °C. More particularly, the invention relates to a laser marking method that allows frozen vials to be labeled, while maintaining the integrity of the biological material contained therein.
The present invention relates to microneedle vaccine formulations, as well as methods of use thereof to provide animals, including canines, protective immunity against infection and disease caused by rabies viruses. Once placed onto the skin of the animals, the microneedle formulations dissolve quickly into the surrounding skin, where the antigens then elicit in the animals high and protective levels of rabies virus neutralizing antibodies.
The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.
This disclosure describes the results of the studies conducted to develop a dissolution method to monitor release profiles of hydrophobic active pharmaceutical ingredients such as ivermectin with or without pyrantel pamoate from a drug product made of complex matrix that includes, but is not limited to beef, tallow, corn cob and soy protein.
This disclosure describes the results of the studies conducted to develop a dissolution method to monitor release profiles of hydrophobic active pharmaceutical ingredients such as ivermectin with or without pyrantel pamoate from a drug product made of complex matrix that includes, but is not limited to beef, tallow, corn cob and soy protein.
The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
The following discloses mammalian cells lines that stably express functional nematode acetylcholine receptor subunits. The resulting expression of functional ion channels has been made possible by the stable co-expression of the chaperone protein, RIC3. These cell lines are extremely useful for the high throughput screening (HTS) of compounds, to identify new candidate parasiticidal, including nematocidal, active ingredients.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
79.
Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A01N 49/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds containing the group wherein m+n≥1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group wherein A means a carbon atom or Y, n ≥ 0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
80.
NOVEL CRYOPRESERVATION BAGS AND METHOD OF USE THEREOF FOR CLOSED SYSTEM, HIGH CAPACITY CELL-BANKING
The disclosure provides a cell freezing and storage bag assembly and a method for using the assembly in banking eukaryotic cells for later seed train expansion. The bag (1) is constructed principally of fluorinated ethylene propylene (FEP) fabric. The bag design includes at least an inlet conduit (2) and an outlet or inoculation conduit (3), which can be sterilely welded to the source of the cells, allowing for "closed system" filling of the bags, which significantly reduces the risk of contamination. The bag also includes a sleeve (8), which can be thermosealed ("S") to form an enclosure, which protects the inlet and outlet conduits against contamination and mechanical damage during freezing, storage and subsequent thawing. In the method, once each bag is filled, its corresponding inlet conduit is sealed ("AS"), and both the inlet and outlet conduits are enclosed within the sleeve. This closed system method obviates the need for sterile environments.
The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing inactivated PEDV. The invention also encompasses epitopes or immunogens which can be used to protect porcine animals against PEDV.
The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions.
The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines.
The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one indole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
H03K 5/04 - Shaping pulses by increasing durationShaping pulses by decreasing duration
H03K 7/00 - Modulating pulses with a continuously-variable modulating signal
85.
PARASITICIDAL COMPOSITIONS COMPRISING INDOLE DERIVATIVES, METHODS AND USES THEREOF
The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one indole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01P 15/00 - Biocides for specific purposes not provided for in groups
The present invention relates to novel anthelmintic compounds of formula (I) below: [Formula should be inserted here] wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X6, X8, Q1, Q2, Q3, Q4, Q5, Q6, Ring A, Ring B, W, W', R2, R3, R, R', m, n and q are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides in ovo injection devices, including a novel vaccine/substance conservation valve (VCV), a needle depth adjuster (NDA), and methods for selectively delivering vaccines and other substances to eggs in the context of poultry hatcheries. The valve of the present invention allows for the conditional dispensing of vaccines and other substances dependent upon the presence or absence of an egg. When an egg is present, the valve becomes activated, allowing vaccines or other substances to be injected. When an egg is absent, the valve is not activated, thus vaccines and other valuable substances are conserved. The NDA allows embryonated eggs to be more safely injected by reducing the depth of needle penetration, particularly in smaller eggs.
The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV.
L'INSTITUT NATIONAL SUPERIEUR DES SCIENCES AGRONOMIQUES DE L' ALIMENTATION ET DE L'ENVIRONNEMENT (France)
L'UNIVERSITE DE BOURGOGNE (France)
Inventor
Genin, Noel Yves Henri Jean
Audonnet, Jean-Christophe
Roy, Didier
Seche, Edouard
Gervais, Patrick
Khaldi-Plassart, Samira
Useo, Romain
De Coninck, Joëlle
Abstract
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.
The present invention provides uses of aryl alkyl malononitrile compounds of formula (I), or veterinarily acceptable salts thereof, for controlling and preventing parasite infestations in animals. The invention also provides methods for controlling and preventing parasite infestation in animals comprising administering an effective amount of at least one aryl alkyl malononitrile compound of formula (I), or a veterinarily acceptable salt thereof, to the animal.
The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
This disclosure provides attenuated Histophilus somni strains, compositions comprising same, and methods of production and use thereof. The attenuated strains may express lower or no levels of various virulence-associated genes, relative to the corresponding pathogenic bacteria Advantageously, the attenuated Histophilus somni strains may be administered orally, intranasally, intra-tracheally, or subcutaneously.
This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.
The invention is a pour-on antiparasitic formulation having superior water resistant properties. The pour-on formulation utilizes one or more polymers (water insoluble with or without water soluble) in the range of about 5 to about 40% w/w, one or more solvents in the range of about 50 to about 94% w/w, with or without additive (e.g., isopropanol or ethanol) in the range of about 5 to about 30% w/w, and optionally a plasticizer in the range of about 0.5 to about 25% w/w. The pour-on antiparasitic formulation features limited spreading when applied to animals (cattle, sheep, dogs and the like). The pour-on antiparasitic formulation further partially evaporates, leaving a water resistant polymer matrix that diffuses at least one active ingredient to the animal's skin.
The invention is a pour-on antiparasitic formulation having superior water resistant properties. The pour-on formulation utilizes one or more polymers (water insoluble with or without water soluble) in the range of about 5 to about 40% w/w, one or more solvents in the range of about 50 to about 94%> w/w, with or without additive (e.g., isopropanol or ethanol) in the range of about 5 to about 30% w/w, and optionally a plasticizer in the range of about 0.5 to about 25% w/w. The pour-on antiparasitic formulation features limited spreading when applied to animals (cattle, sheep, dogs and the like). The pour-on antiparasitic formulation further partially evaporates, leaving a water resistant polymer matrix that diffuses at least one active ingredient to the animal's skin.
The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
The present invention relates to novel dihydroazole of formula (I) and salts thereof:
2, G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.
C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
C07D 235/08 - Radicals containing only hydrogen and carbon atoms
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.
